Takeda Begins Development of Coronavirus (COVID-19) Treatment
Council member Takeda Pharmaceutical Company has joined several other drug companies in the race to develop an approved treatment for the novel coronavirus (COVID-19).
Takeda’s drug would be made from the plasma of people who developed immunity from the virus through natural recovery or a non-approved treatment for the virus, and would be aimed toward those who are susceptible to disease. Previous treatments derived from plasma have been effective in treating other viral infections according to Takeda, providing hope that the drug company can translate that success to a coronavirus treatment. Takeda, working with the U.S. government, as well as officials in several Asian and European countries, aim to develop a treatment “within nine to 18 months,” as the prospect of an approved vaccine still remains months away.
“As a company dedicated to the health and well-being of people around the world, we will do all that we can to address the novel coronavirus threat,” Dr. Rajeev Venkayya, president of Takeda’s vaccine business unit, said in a statement. “We have identified relevant assets and capabilities across the company and are hopeful that we can expand the treatment options for patients with Covid-19 and the providers caring for them.”
The Council praises Takeda for its quick and important work to help curb the spread of the virus. NEC also urges its members to stay healthy and informed.
Recently from the Blog
November 24 Weekly Round-Up: NEC Members Contribute to COVID-19 Crisis Response